Quinupristin-dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens.

BACKGROUND The combination of the streptogramins quinupristin and dalfopristin was approved in the United States in late 1999 for the treatment of vancomycin-resistant Enterococcus faecium infections. Since 1974, another streptogramin, virginiamycin, has been used at subtherapeutic concentrations to promote the growth of farm animals, including chickens. METHODS To determine the frequency of quinupristin-dalfopristin-resistant E. faecium, we used selective medium to culture samples from chickens purchased in supermarkets in Georgia, Maryland, Minnesota, and Oregon and stool samples from outpatients. RESULTS Between July 1998 and June 1999, samples from 407 chickens from 26 stores in four states were cultured, as were 334 stool samples from outpatients. Quinupristin-dalfopristin-resistant E. faecium was isolated from 237 chicken carcasses and 3 stool specimens. The resistant isolates from stool had low-level resistance (minimal inhibitory concentration [MIC], 4 microg per milliliter; resistance was defined as a MIC of at least 4 microg per milliliter). The resistant isolates from chickens in general had higher levels of resistance (MICs ranging from 4 to 32 microg per milliliter; MIC required to inhibit 50 percent of isolates, 8 microg per milliliter). CONCLUSIONS Quinupristin-dalfopristin-resistant E. faecium contaminates a large proportion of chickens sold in U.S. supermarkets. However, the low prevalence and low level of resistance of these strains in human stool specimens suggest that the use of virginiamycin in animals has not yet had a substantial influence. Foodborne dissemination of resistance may increase, however, as the clinical use of quinupristin-dalfopristin increases.

[1]  G. Montay,et al.  The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. , 1997, The Journal of antimicrobial chemotherapy.

[2]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .

[3]  A. Voss,et al.  VRE and meat , 1997, The Lancet.

[4]  R N Jones,et al.  Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. , 1995, Diagnostic microbiology and infectious disease.

[5]  F M Aarestrup,et al.  Occurrence of glycopeptide resistance among Enterococcus faecium isolates from conventional and ecological poultry farms. , 1995, Microbial drug resistance.

[6]  J. Bates,et al.  Faecal carriage and nosocomial spread of vancomycin-resistant Enterococcus faecium. , 1994, The Journal of antimicrobial chemotherapy.

[7]  L. Rice,et al.  Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. , 1999, The Journal of infectious diseases.

[8]  G. Eliopoulos,et al.  Characterization of Vancomycin-Resistant Enterococcus faecium Isolates from the United States and Their Susceptibility In Vitro to Dalfopristin-Quinupristin , 1998, Antimicrobial Agents and Chemotherapy.

[9]  J. Coffman.  The use of drugs in food animals: benefits and risks. , 1999 .

[10]  A. Voss,et al.  Antimicrobial Susceptibility Patterns of Enterococci Causing Infections in Europe , 1999, Antimicrobial Agents and Chemotherapy.

[11]  N. E. Jensen,et al.  Surveillance of antimicrobial resistance in bacteria isolated from food animals to antimicrobial growth promoters and related therapeutic agents in Denmark , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[12]  N. Woodford,et al.  Mechanisms of Resistance to Quinupristin-Dalfopristin among Isolates of Enterococcus faecium from Animals, Raw Meat, and Hospital Patients in Western Europe , 2000, Antimicrobial Agents and Chemotherapy.

[13]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[14]  H. Goossens,et al.  Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients. , 1995, Journal of clinical microbiology.

[15]  P. Mertens,et al.  High prevalence of colonization with vancomycin- and pristinamycin-resistant enterococci in healthy humans and pigs in The Netherlands: is the addition of antibiotics to animal feeds to blame? , 1997, The Journal of antimicrobial chemotherapy.

[16]  S. Handwerger,et al.  Persistence of vancomycin-resistant Enterococcus faecium gastrointestinal tract colonization in antibiotic-treated mice. , 1996, Microbial drug resistance.

[17]  F. K. Gould,et al.  Use of cephalexin-aztreonam-arabinose agar for selective isolation of Enterococcus faecium , 1994, Journal of clinical microbiology.

[18]  F. Aarestrup,et al.  Occurrence of satA and vgb Genes in Streptogramin-Resistant Enterococcus faecium Isolates of Animal and Human Origins in The Netherlands , 1998, Antimicrobial Agents and Chemotherapy.

[19]  J. Bates,et al.  Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man. , 1994, The Journal of antimicrobial chemotherapy.

[20]  R. Leclercq,et al.  Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. , 1996, The Journal of infectious diseases.

[21]  E. Dejesus,et al.  Gastrointestinal tract colonization with vancomycin-resistant Enterococcus faecium in an animal model , 1996, Antimicrobial agents and chemotherapy.

[22]  J. Duval,et al.  Identification of the satA gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145 , 1993, Antimicrobial Agents and Chemotherapy.

[23]  M. Zervos,et al.  Antimicrobial Resistance in Enterococci Isolated from Turkey Flocks Fed Virginiamycin , 1998, Antimicrobial Agents and Chemotherapy.

[24]  J J Schentag,et al.  Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. , 1998, Diagnostic microbiology and infectious disease.

[25]  A. Caprioli,et al.  Decrease of vancomycin-resistant enterococci in poultry meat after avoparcin ban , 1999, The Lancet.

[26]  H. Claus,et al.  Decreased incidence of VanA-type vancomycin-resistant enterococci isolated from poultry meat and from fecal samples of humans in the community after discontinuation of avoparcin usage in animal husbandry. , 1999, Microbial drug resistance.

[27]  A. Sundsfjord,et al.  Continuing high prevalence of VanA‐type vancomycin‐resistant enterococci on Norwegian poultry farms three years after avoparcin was banned , 2000, Journal of applied microbiology.

[28]  J. Top,et al.  Enterococci with Glycopeptide Resistance in Turkeys, Turkey Farmers, Turkey Slaughterers, and (Sub)Urban Residents in the South of The Netherlands: Evidence for Transmission of Vancomycin Resistance from Animals to Humans? , 1999, Antimicrobial Agents and Chemotherapy.

[29]  L. Jensen,et al.  Horizontal Transfer of the satA Gene Encoding Streptogramin A Resistance Between Isogenic Enterococcus faecium Strains in the Gastrointestinal Tract of Gnotobiotic Rats , 1999 .

[30]  M. Marsilio,et al.  Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database--USA. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  H. Claus,et al.  vanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry. , 1995, FEMS microbiology letters.

[32]  Nicole,et al.  Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands , 1997, Journal of clinical microbiology.

[33]  F. Aarestrup,et al.  Detection of the satA gene and transferability of virginiamycin resistance in Enterococcus faecium from food-animals. , 1998, FEMS microbiology letters.

[34]  F. Aarestrup,et al.  Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. , 1999, Emerging infectious diseases.